Evidence map›Paper›PMID 35967366›Full record

ArticleFrontiers in immunology2022

A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.

Mingyi Yang, Haishi Zheng, Ke Xu, Qiling Yuan, Yirixaiti Aihaiti, Yongsong Cai, Peng Xu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Musculoskeletal disorders: does cuproptosis hold the key?Frontiers in cell and developmental biology · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mingyi YangDepartment of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, China.
Haishi ZhengDepartment of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, China.
Ke XuDepartment of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, China.
Qiling YuanDepartment of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, China.
Yirixaiti AihaitiDepartment of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, China.
Yongsong CaiDepartment of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, China.
Peng XuDepartment of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, China.
Xi'an Honghui Hospital · CNXi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Osteosarcoma (OS) is a common bone malignancy with poor prognosis. We aimed to investigate the relationship between cuproptosis-related lncRNAs (CRLncs) and the survival outcomes of patients with OS. Methods: Transcriptome and clinical data of 86 patients with OS were downloaded from The Cancer Genome Atlas (TCGA). The GSE16088 dataset was downloaded from the Gene Expression Omnibus (GEO) database. The 10 cuproptosis-related genes (CRGs) were obtained from a recently published article on cuproptosis in Results: Six CRLncs that can guide OS prognosis and immune microenvironment were obtained, including three high-risk CRLncs (AL645608.6, AL591767.1, and UNC5B-AS1) and three low-risk CRLncs (CARD8-AS1, AC098487.1, and AC005041.3). Immune cells such as B cells, macrophages, T-helper type 2 (Th2) cells, regulatory T cells (Treg), and immune functions such as APC co-inhibition, checkpoint, and T-cell co-inhibition were significantly downregulated in high-risk groups. In addition, we obtained four drugs with potential efficacy for OS: AUY922, bortezomib, lenalidomide, and Z.LLNle.CHO. The expression of LIPT1, DLAT, and FDX1 at both mRNA and protein levels was significantly elevated in OS cell lines compared with normal osteoblast hFOB1.19. The mRNA expression level of AL591767.1 was decreased in OS, and that of AL645608.6, CARD8-AS1, AC005041.3, AC098487.1, and UNC5B-AS1 was upregulated in OS. Conclusion: CRLncs that can guide OS prognosis and the immune microenvironment and drugs that may have a potential curative effect on OS obtained in this study provide a theoretical basis for OS survival research and clinical decision-making.

Indexed as

ApoptosisOsteosarcomaRNA, Long NoncodingBiomarkers, TumorCARD Signaling Adaptor ProteinsCopperGene Expression ProfilingGene Expression Regulation, NeoplasticHumansNeoplasm ProteinsNetrin ReceptorsPrognosisRNA, MessengerTumor MicroenvironmentBiomarkers, TumorCARD8 protein, humanCARD Signaling Adaptor ProteinsCopperNeoplasm ProteinsNetrin ReceptorsRNA, Long NoncodingRNA, MessengerUNC5B protein, humancuproptosisimmunityLncRNAosteosarcomaprognosis

Identifiers

PMID35967366
PMCPMC9373797
OpenAlexW4288698320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.